Premier Biomedical/UTEP Demonstrate New Anti-Cancer Immunotherapy Drug; May Compete Against Best of Big Pharma Drugs
El Paso, TX -- (ReleaseWire) -- 04/25/2016 -- Premier Biomedical, Inc. (OTCQB:BIEI) revealed the results of its latest cancer immunotherapy work being conducted by its research partner, UTEP, at the recent American Association for Cancer Research (AACR) Conference, in New Orleans. The patent-pending anti-cancer antibody is intended to compete in the immunotherapy segment of the $100 plus billion cancer treatment market, with drugs like Yervoy® by Bristol Meyers Squibb who is projecting sales of $14 billion by 2018.
William A. Hartman, President and CEO of Premier Biomedical, stated, "This new drug has shown to be effective in blocking 98.8% of CTLA-4 breast cancer-causing antigens in laboratory tests, compared to 36% for the drug we presented in 2014. In our mouse testing, both of these antibodies demonstrated immunity to re-injections of breast cancer after treatment."
Hartman indicated that the company plans comparison tests of other available immunotherapy drugs to verify the belief that this new antibody may be the most effective anti-breast cancer drug in the world. "We have also developed antibodies against other cancer-causing antigens and plan animal tests to compare them to other available treatments in the near future," he said.
Contact William A. Ha
